Revenue: As of FY2025 Q1, the actual value is USD 1.854 M.EPS: As of FY2025 Q1, the actual value is USD -0.16.<h3>Segment Revenue</h3><ul><li>Diagnostic R&amp;D: No revenue reported for the three months ended March 31, 2025, compared to $2,885 for the same period in 2024.</li><li>Laboratory Services: Revenue of $1,853,597 for the three months ended March 31, 2025, compared to $2,403,506 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: The net loss for the three months ended March 31, 2025, was - $2,660,417, compared to - $1,961,815 for the same period in 2024.</li><li>Operating Expenses: Total operating expenses were $4,480,736 for the three months ended March 31, 2025, compared to $4,351,621 for the same period in 2024.</li><li>Loss from Operations: Loss from operations was - $2,627,139 for the three months ended March 31, 2025, compared to - $1,945,230 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $1,641,775 for the three months ended March 31, 2025, compared to - $2,345,975 for the same period in 2024.</li><li>Net Cash Used in Investing Activities: - $50,786 for the three months ended March 31, 2025, compared to - $41,387 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $1,031,976 for the three months ended March 31, 2025, compared to $2,018,957 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>CyPath® Lung Testing Revenue: Increased approximately 275% to $169,000 for the three months ended March 31, 2025, compared to $45,000 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to improve financial performance and accelerate the commercial growth of CyPath® Lung, aiming for $3 to $4 million in annual cost savings at its subsidiary Precision Pathology Laboratory Services (PPLS), while increasing resources to expand CyPath® Lung sales in high-potential national markets.</li><li>Non-Core Business: The company intends to seek strategic partners to develop therapeutic discoveries which could result in broad-spectrum cancer treatments in the future.</li></ul>

BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM) | 10-Q: FY2025 Q1 Revenue: USD 1.854 M